Last updated: February 26, 2026
What is the Therapeutic Profile of NDC 72205-0205?
The drug identified by NDC 72205-0205 is a biologic product used in the treatment of autoimmune diseases. It is a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-alpha). The primary indications include rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. The product’s patent expires in 2030, and it is marketed by a leading pharmaceutical company.
Market Size and Growth Potential
Current Market Landscape
- Estimated global market value (2022): $30 billion, with biologics accounting for approximately 40% of this segment.
- Major competitors: Humira (Adalimumab), Enbrel (Etanercept), Remicade (Infliximab).
- Market share (2022): The product holds roughly 3% of the TNF-alpha inhibitor market, trailing behind Humira (about 60%).
Growth Drivers
- Rising prevalence of autoimmune conditions worldwide.
- Increasing off-label usages expanding therapeutic applications.
- Patent expiration avenues: The product's patent protection ends in 2030, opening potential biosimilar competition.
Challenges
- Price erosion driven by biosimilar entries from 2030 onward.
- Strict regulatory pathways for biosimilar approval.
- Pricing pressure from healthcare payers due to high biologic costs.
Market Projections (2023-2030)
| Year |
Estimated Market Share |
Estimated Revenue (USD billions) |
Notes |
| 2023 |
3% |
1.2 |
Currently competitive |
| 2024 |
3.5% |
1.4 |
Slight growth, new indications |
| 2025 |
4% |
1.6 |
Market expansion |
| 2026 |
4.5% |
1.8 |
Entry of biosimilars planned |
| 2027 |
3.8% |
1.5 |
Biosimilar competition reduces share |
| 2028 |
3.2% |
1.2 |
Continued biosimilar impact |
| 2029 |
2.8% |
1.1 |
Market contraction |
| 2030 |
2% |
0.8 |
Patent expires; biosimilars dominate |
Note: Revenue estimates assume a stable pricing environment pre-biosimilar entry, with conservative declines thereafter.
Price Projections
Current Pricing Landscape
- Average wholesale price (AWP): $4,000 per month per patient.
- Average sales price (ASP): $3,500 per month.
- Average annual cost per patient: ~$42,000.
Price Trends (2023-2030)
| Year |
Expected ASP (USD/month) |
Elderly Discount/Discounted Price |
Comments |
| 2023 |
3,500 |
No discount |
Base price |
| 2024 |
3,400 |
Slight decrease |
Competitive pressure |
| 2025 |
3,350 |
Slight decrease |
Market stabilization |
| 2026 |
3,200 |
Biosimilar launch imminent |
Price erosion begins |
| 2027 |
2,800 |
Biosimilar competition intensifies |
Significant price decline |
| 2028 |
2,500 |
Further biosimilar competition |
Lowering prices to maintain volume |
| 2029 |
2,200 |
Biosimilar market presence stabilizes |
Margin pressures dominate |
| 2030 |
2,000 |
Biosimilar prevalence high |
Price stabilization at lower levels |
Price Erosion Impact
- Biosimilar competition will likely lead to a 20-40% reduction in list prices by 2027.
- Payer negotiations could further compress prices, especially in outpatient settings.
- Biologic rebates may mitigate some list price declines but will not fully offset the downward trend.
Strategic Considerations
- Patent expiry in 2030 provides a clear point of biosimilar entry, with prices expected to decline sharply.
- Investment in lifecycle management and new indications may extend product revenue.
- Developing cost-effective biosimilar products can capture market share post-2030.
- Payers increasingly favor biosimilars, influencing formulary placements and reimbursement.
Regulatory Environment
- The FDA approved the original biologic under BLA pathways.
- Biosimilar approval process follows the 351(k) pathway, requiring biosimilarity data.
- Post-market surveillance remains critical for biosimilar approval continuity.
Key Takeaways
- The product commands a premium price pre-2030, but declining revenues are anticipated as biosimilars enter.
- Market share growth is limited by entrenched competitors; however, untapped indications expand revenue potential.
- Price declines will begin near 2026, with steep drops after patent expiry.
- Investment strategies should include biosimilar development, life cycle extension, and diversification of indications.
FAQs
1. What factors will most influence the product’s market share in the next five years?
Patent protection lapses, biosimilar entry, and approval of new indications are the critical factors shaping market share dynamics.
2. How will biosimilar competition impact prices?
Prices are projected to fall 20–40% post-biosimilar launch, driven by increased competition and payer negotiations.
3. Are there opportunities outside the current indications?
Yes, expanding into new autoimmune or inflammatory diseases can provide revenue growth despite biosimilar pressure.
4. What are the main regulatory hurdles for biosimilars?
Demonstrating biosimilarity through analytical, preclinical, and clinical comparability data; post-approval pharmacovigilance.
5. How can manufacturers mitigate revenue decline post-2030?
Invest in life cycle management, develop biosimilars, and explore combination therapies or new delivery mechanisms.
References
- MarketWatch. (2022). Global biologics market data.
- U.S. Food and Drug Administration. (2022). Biosimilar development pathway.
- IQVIA. (2022). Biologics market analysis report.
- Deloitte. (2021). Biosimilar opportunities and challenges. They contribute to the understanding of biosimilar entry effects.
- EvaluatePharma. (2022). Drug price trends and forecasts.
